<DOC>
	<DOCNO>NCT01069367</DOCNO>
	<brief_summary>This evaluate immunogenicity base EMEA/CHMP criterion , safety &amp; tolerability cell-derived A/H1N1 influenza HA vaccine healthy Japanese elderly subject .</brief_summary>
	<brief_title>Open-label , Uncontrolled Postmarketing Study Cell-derived A/H1N1 Influenza HA Vaccine Japanese Elderly Subjects</brief_title>
	<detailed_description>This open-label , uncontrolled post-marketing study cell-derived A/H1N1 influenza HA vaccine . Subjects receive 3.75Î¼g cell-derived H1N1sw vaccine formulate half ( i.e. , half content European-licensed adjuvanted seasonal influenza vaccine ) MF59 adjuvant ( 3.75_halfMF59 ) . All vaccination administer IM deltoid muscle , preferably non-dominant arm first vaccination opposite arm first vaccination , rule , second vaccination . Blood sample collect baseline ( day1 ) , 3 week first vaccination ( day 22 ) three week second vaccination ( day 43 ) . Sera test Hemagglutination Inhibition ( HI ) assay . Local systemic reaction collect first week follow injection use Diary Card ( i.e . Day 1 Day 7 Day 22 Day 28 ) . All AEs , SAEs , AEs lead withdrawal study relate prescription medication collect entire study period .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy Japanese age 60 year Any serious chronic progressive disease accord judgment investigator ( include , limited neoplasm , insulin dependent diabetes , cardiac , renal , hepatic respiratory disease ) History anaphylaxis , serious vaccine reaction , hypersensitivity influenza viral protein , excipients Administration swine influenza ( A/H1N1 ) vaccine prior Day 1 document confirm suspected swine influenza disease History progressive sever neurological disorder Known suspected impairment/alteration immune function</criteria>
	<gender>All</gender>
	<minimum_age>61 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Influenza A</keyword>
	<keyword>H1N1 subtype</keyword>
	<keyword>Children/adolescent</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Adjuvant</keyword>
	<keyword>Cell culture</keyword>
</DOC>